EASL International Liver Congress™ 2023
Jun 23, 2023 at 8:30 AM CEST
Oral Presentation: OS-063 Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, Significantly Reduces Liver Fat, Fibroinflammation, and Body Weight in Patients with Non-alcoholic Fatty Liver Disease: a 24-week Multicenter, Randomized, Double-blind, Placebo-controlled Trial
Presenter: Stephen A. Harrison, MD, Medical Director, Pinnacle Clinical Research and Adjunct Professor of Medicine, Oxford University
